Valacyclovir compared with valganciclovir to prevent CMV and EBV infection after kidney transplant
Compares two antiviral drugs for preventing CMV and EBV in kidney transplant recipients.
Plain-language title generated from the registry record
Registry title: Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
Key facts
- Where
- Taipei, TaiwanSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and adults who are about to have, or just had, a kidney transplant. It compares two antiviral medicines that prevent CMV and EBV infection.
- Age
- At least 3 years old.
- Sex
- Men and women can join.
- Disease stage
- About to receive a kidney transplant, or received one within the past 2 weeks before screening. No active CMV or EBV virus in the blood.
- Earlier treatment
- Will receive medicine to prevent CMV and/or EBV infection, as decided by the transplant surgeon.
- Biomarker or test result
- No detectable CMV or EBV viral load (PCR test) at screening.
Main reasons for not taking part
- Severe other illnesses that make taking part unsafe, as judged by the transplant surgeon
- Pregnancy
- Known allergy to both valacyclovir and valganciclovir
This trial only enrols participants who have had an organ transplant. The registry sentence this rests on: Patients who are about to receive or just received kidney transplantation within the past 2 weeks before the date of screening.
Read by machine on 12 November 2026.
Where in Taiwan
- National Taiwan University HospitalTaipei, TaiwanContact: Hou-Xuan Huang, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- National Taiwan University Hospital
- Trial code
- NCT07294547
- Record updated
- 19 December 2025
- Original description
Opportunistic CMV viremia (primary infection or reactivation) is usually managed by taking prophylactic medication for both adult and pediatric kidney transplant patients. Most hospitals prescribe valganciclovir for this purpose but valacyclovir has also been used. The most unfavorable side effect of valganciclovir is bone marrow suppression which can be troublesome for kidney transplant patients who are already immunosuppressed. We aim to assess the non-inferiority of valacyclovir compared with valganciclovir in this study.Read full original descriptionShow less
Non-Inferiority Assessment of Valacyclovir Versus Valganciclovir as Prophylaxis Against CMV and EBV Viremia in Kidney Transplant Recipients: A Single-Center Prospective Randomized Pilot Study.
Opportunistic CMV viremia (primary infection or reactivation) is usually managed by taking prophylactic medication for both adult and pediatric kidney transplant patients. Most hospitals prescribe valganciclovir for this purpose but valacyclovir has also been used. The most unfavorable side effect of valganciclovir is bone marrow suppression which can be troublesome for kidney transplant patients who are already immunosuppressed. We aim to assess the non-inferiority of valacyclovir compared with valganciclovir in this study.
Inclusion: Age at least 3 years of age; Patients who are about to receive or just received kidney transplantation within the past 2 weeks before the date of screening; Will be receiving prophylactic antiviral therapy against CMV and/or EBV per discretion of transplant surgeon; No active CMV or EBV viremia (as defined by detectable viral load PCR) at the time of screening; Ability and willingness of the patient (or parent/legal guardian for minors) to provide informed consent and comply with study procedures.
Exclusion: Severe co-morbidities that would preclude safe participation as judged by the transplant surgeon; Known allergy to both valacyclovir and valganciclovir; Pregnancy (valganciclovir is likely teratogenic).